Literature DB >> 30137421

Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group.

Raymond Y Huang1, Wenya Linda Bi2, Michael Weller3, Thomas Kaley4, Jaishri Blakeley5, Ian Dunn2, Evanthia Galanis6, Matthias Preusser7, Michael McDermott8, Leland Rogers9, Jeffrey Raizer10, David Schiff11, Riccardo Soffietti12, Jörg-Christian Tonn13, Michael Vogelbaum14, Damien Weber15, David A Reardon16, Patrick Y Wen16.   

Abstract

No standard criteria exist for assessing response and progression in clinical trials involving patients with meningioma, and there is no consensus on the optimal endpoints for trials currently under way. As a result, there is substantial variation in the design and response criteria of meningioma trials, making comparison between trials difficult. In addition, future trials should be designed with accepted standardized endpoints. The Response Assessment in Neuro-Oncology Meningioma Working Group is an international effort to develop standardized radiologic criteria for treatment response for meningioma clinical trials. In this proposal, we present the recommendations for response criteria and endpoints for clinical trials involving patients with meningiomas.

Entities:  

Year:  2019        PMID： 30137421      PMCID： PMC6303427          DOI： 10.1093/neuonc/noy137

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


  28 in total

1.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Authors:  Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

Review 2.  Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.

Authors:  Benjamin M Ellingson; Martin Bendszus; Jerrold Boxerman; Daniel Barboriak; Bradley J Erickson; Marion Smits; Sarah J Nelson; Elizabeth Gerstner; Brian Alexander; Gregory Goldmacher; Wolfgang Wick; Michael Vogelbaum; Michael Weller; Evanthia Galanis; Jayashree Kalpathy-Cramer; Lalitha Shankar; Paula Jacobs; Whitney B Pope; Dewen Yang; Caroline Chung; Michael V Knopp; Soonme Cha; Martin J van den Bent; Susan Chang; W K Al Yung; Timothy F Cloughesy; Patrick Y Wen; Mark R Gilbert
Journal:  Neuro Oncol       Date:  2015-08-05       Impact factor: 12.300

Review 3.  Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review.

Authors:  Thomas Kaley; Igor Barani; Marc Chamberlain; Michael McDermott; Katherine Panageas; Jeffrey Raizer; Leland Rogers; David Schiff; Michael Vogelbaum; Damien Weber; Patrick Wen
Journal:  Neuro Oncol       Date:  2014-02-04       Impact factor: 12.300

4.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

Authors:  Quinn T Ostrom; Haley Gittleman; Peter Liao; Chaturia Rouse; Yanwen Chen; Jacqueline Dowling; Yingli Wolinsky; Carol Kruchko; Jill Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

Review 5.  Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review.

Authors:  Leland Rogers; Igor Barani; Marc Chamberlain; Thomas J Kaley; Michael McDermott; Jeffrey Raizer; David Schiff; Damien C Weber; Patrick Y Wen; Michael A Vogelbaum
Journal:  J Neurosurg       Date:  2015-01       Impact factor: 5.115

6.  Pseudoprogression in boron neutron capture therapy for malignant gliomas and meningiomas.

Authors:  Shin-Ichi Miyatake; Shinji Kawabata; Naosuke Nonoguchi; Kunio Yokoyama; Toshihiko Kuroiwa; Hideki Matsui; Koji Ono
Journal:  Neuro Oncol       Date:  2009-03-16       Impact factor: 12.300

7.  Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.

Authors:  Jedd D Wolchok; Axel Hoos; Steven O'Day; Jeffrey S Weber; Omid Hamid; Celeste Lebbé; Michele Maio; Michael Binder; Oliver Bohnsack; Geoffrey Nichol; Rachel Humphrey; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

8.  Hitting a moving target: evolution of a treatment paradigm for atypical meningiomas amid changing diagnostic criteria.

Authors:  Blake E Pearson; James M Markert; Winfield S Fisher; Barton L Guthrie; John B Fiveash; Cheryl A Palmer; Kristen Riley
Journal:  Neurosurg Focus       Date:  2008       Impact factor: 4.047

Review 9.  Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.

Authors:  Hideho Okada; Michael Weller; Raymond Huang; Gaetano Finocchiaro; Mark R Gilbert; Wolfgang Wick; Benjamin M Ellingson; Naoya Hashimoto; Ian F Pollack; Alba A Brandes; Enrico Franceschi; Christel Herold-Mende; Lakshmi Nayak; Ashok Panigrahy; Whitney B Pope; Robert Prins; John H Sampson; Patrick Y Wen; David A Reardon
Journal:  Lancet Oncol       Date:  2015-11       Impact factor: 41.316

Review 10.  EANO guidelines for the diagnosis and treatment of meningiomas.

Authors:  Roland Goldbrunner; Giuseppe Minniti; Matthias Preusser; Michael D Jenkinson; Kita Sallabanda; Emmanuel Houdart; Andreas von Deimling; Pantelis Stavrinou; Florence Lefranc; Morten Lund-Johansen; Elizabeth Cohen-Jonathan Moyal; Dieta Brandsma; Roger Henriksson; Riccardo Soffietti; Michael Weller
Journal:  Lancet Oncol       Date:  2016-08-30       Impact factor: 41.316
View more
  37 in total

1.  DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management.

Authors:  Farshad Nassiri; Yasin Mamatjan; Suganth Suppiah; Jetan H Badhiwala; Sheila Mansouri; Shirin Karimi; Olli Saarela; Laila Poisson; Irina Gepfner-Tuma; Jens Schittenhelm; Ho-Keung Ng; Houtan Noushmehr; Patrick Harter; Peter Baumgarten; Michael Weller; Matthias Preusser; Christel Herold-Mende; Marcos Tatagiba; Ghazaleh Tabatabai; Felix Sahm; Andreas von Deimling; Gelareh Zadeh; Kenneth D Aldape
Journal:  Neuro Oncol       Date:  2019-07-11       Impact factor: 12.300

Review 2.  Multimodality Therapy of Patients with Refractory Meningiomas.

Authors:  Haroon Ahmad; David Schiff
Journal:  Curr Treat Options Oncol       Date:  2019-05-09

3.  Stereotactic radiosurgery versus active surveillance for incidental, convexity meningiomas: a matched cohort analysis from the IMPASSE study.

Authors:  Stylianos Pikis; Georgios Mantziaris; Abdurrahman I Islim; Selcuk Peker; Yavuz Samanci; Ahmed M Nabeel; Wael A Reda; Khaled Abdelkarim; Amr M N El-Shehaby; Sameh R Tawadros; Reem M Emad; Violaine Delabar; David Mathieu; Cheng-Chia Lee; Huai-Che Yang; Roman Licsak; Jaromir Hanuska; Roberto Martinez Alvarez; Dev N Patel; Douglas Kondziolka; Kenneth Bernstein; Nuria Martinez Moreno; Manjul Tripathi; Herwin Speckter; Camilo Albert; Greg N Bowden; Ronald J Benveniste; Dade L Lunsford; Michael D Jenkinson; Jason Sheehan
Journal:  J Neurooncol       Date:  2022-01-29       Impact factor: 4.130

4.  Microscopic brain invasion in meningiomas previously classified as WHO grade I is not associated with patient outcome.

Authors:  Annamaria Biczok; Christine Jungk; Rupert Egensperger; Andreas von Deimling; Bogdana Suchorska; Joerg C Tonn; Christel Herold-Mende; Christian Schichor
Journal:  J Neurooncol       Date:  2019-11-11       Impact factor: 4.130

5.  Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results.

Authors:  Wenya Linda Bi; Lakshmi Nayak; David M Meredith; Joseph Driver; Ziming Du; Samantha Hoffman; Yvonne Li; Eudocia Quant Lee; Rameen Beroukhim; Mikael Rinne; Ricardo McFaline-Figueroa; Ugonma Chukwueke; Christine McCluskey; Sarah Gaffey; Andrew D Cherniack; Jennifer Stefanik; Lisa Doherty; Christina Taubert; Meghan Cifrino; Deborah LaFrankie; Thomas Graillon; Patrick Y Wen; Keith L Ligon; Ossama Al-Mefty; Raymond Y Huang; Alona Muzikansky; E Antonio Chiocca; Sandro Santagata; Ian F Dunn; David A Reardon
Journal:  Neuro Oncol       Date:  2022-01-05       Impact factor: 12.300

6.  Role of 3D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study.

Authors:  Thomas Graillon; Loic Ferrer; Jason Siffre; Marc Sanson; Matthieu Peyre; Hadrien Peyrière; Grégory Mougel; Didier Autran; Emeline Tabouret; Dominique Figarella-Branger; Anne Barlier; Michel Kalamarides; Henry Dufour; Thierry Colin; Olivier Chinot
Journal:  Neuro Oncol       Date:  2021-07-01       Impact factor: 12.300

7.  Stereotactic radiosurgery versus active surveillance for asymptomatic, skull-based meningiomas: an international, multicenter matched cohort study.

Authors:  Georgios Mantziaris; Stylianos Pikis; Yavuz Samanci; Selcuk Peker; Ahmed M Nabeel; Wael A Reda; Sameh R Tawadros; Amr M N El-Shehaby; Khaled Abdelkarim; Reem M Emad; Violaine Delabar; David Mathieu; Cheng-Chia Lee; Huai-Che Yang; Roman Liscak; Jaromir Hanuska; Roberto Martinez Alvarez; Nuria Martinez Moreno; Manjul Tripathi; Herwin Speckter; Camilo Albert; Ronald J Benveniste; Greg N Bowden; Dev N Patel; Douglas Kondziolka; Kenneth Bernstein; L Dade Lunsford; Michael D Jenkinson; Abdurrahman I Islim; Jason Sheehan
Journal:  J Neurooncol       Date:  2022-01-24       Impact factor: 4.130

8.  In vivo imaging of cell proliferation in meningioma using 3'-deoxy-3'-[18F]fluorothymidine PET/MRI.

Authors:  Asma Bashir; Tina Binderup; Mark Bitsch Vestergaard; Helle Broholm; Lisbeth Marner; Morten Ziebell; Kåre Fugleholm; Andreas Kjær; Ian Law
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-02-11       Impact factor: 9.236

9.  Intraarterial Administration Boosts 177Lu-HA-DOTATATE Accumulation in Salvage Meningioma Patients.

Authors:  Evert-Jan P A Vonken; Rutger C G Bruijnen; Tom J Snijders; Tatjana Seute; Marnix G E H Lam; Bart de Keizer; Arthur J A T Braat
Journal:  J Nucl Med       Date:  2021-07-22       Impact factor: 10.057

10.  The growth rate and clinical outcomes of radiation induced meningioma undergoing treatment or active monitoring.

Authors:  Conor S Gillespie; Abdurrahman I Islim; Basel A Taweel; Christopher P Millward; Siddhant Kumar; Nitika Rathi; Shaveta Mehta; Brian J Haylock; Nicola Thorp; Catherine E Gilkes; David D A Lawson; Samantha J Mills; Emmanuel Chavredakis; Jibril Osman Farah; Andrew R Brodbelt; Michael D Jenkinson
Journal:  J Neurooncol       Date:  2021-04-22       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.